Clinical review report: Emicizumab (Hemlibra) Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A.
The objective of this report is to perform a systematic review of the beneficial and harmful effects of emicizumab injection for the treatment of hemophilia A (congenital factor VIII (FVIII) deficiency) in patients without FVIII inhibitors as routine prophylaxis to prevent bleeding or reduce the fre...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
February 2021, 2021
|
| Edition: | Final (with redactions) |
| Series: | CADTH drug reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of emicizumab injection for the treatment of hemophilia A (congenital factor VIII (FVIII) deficiency) in patients without FVIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes |
|---|---|
| Physical Description: | 1 PDF file (112 pages) illustrations |